CVS hedges on 2022 earnings growth target as COVID-19 uncertainty persists
- Wall Street closes rollercoaster week sharply lower
- Invesco (IVZ) Reportedly in Talks to Merge With State Street's (STT) Asset Management Business, Citi Sees More Cons than Pros
- FDA Votes "No" on Pfizer (PFE) Booster for 16+ Age Group, 2 Yes 16 No
- Jefferies Raises Price Targets on Alphabet (GOOGL) and Facebook (FB) as They Are Still Inexpensive Relative to Growth, Reiterates Snap (SNAP) as a Best Growth Idea
- Tesla (TSLA) Could Deliver 900K EV Units This Year and 1.3M in 2022 - Wedbush
FILE PHOTO: People walk by a CVS Pharmacy store in the Manhattan borough of New York City, New York, U.S., November 30, 2017. REUTERS/Shannon Stapleton
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
(Reuters) -CVS Health Corp on Wednesday hedged a bit on its long-term target for double-digit earnings growth for next year, pointing to uncertainty around COVID-19 vaccination and testing demand, as well as medical costs, sending shares down 3%.
"Double-digit adjusted EPS growth remains the benchmark that we're always trying to achieve," said Chief Financial Officer Shawn Guertin. "But an awful lot has changed since 2019 when that target was out there and stated."
CVS said it sees a slight rise in 2021 medical costs as it expects some uptick in COVID-19 vaccination and treatment costs and normalization of demand for non-pandemic healthcare services by the fourth quarter.
Uncertainty caused by a recent surge in COVID-19 cases due to the more contagious Delta variant of the coronavirus led CVS to assume a higher estimate of COVID-related costs in the second half of the year, the company said.
CVS cut its 2021 expectations for the number of COVID-19 vaccine doses it would administer at its clinics to a range of 32 million to 36 million, from its prior view of 29 million to 44 million doses, reflecting a slowdown in vaccinations during the second quarter.
CVS Chief Executive Karen Lynch said in an interview that the company has started seeing an increase in vaccinations, the majority of which are for first doses, as cases have increased due to the Delta variant.
Drugstore chain Walgreens Boots Alliance Inc also said on Wednesday that vaccinations had picked up, mostly in Southern states.
CVS CFO Guertin said that strength in sales of its pharmacy services and health insurance products, lower COVID-related costs and overall cost savings initiatives could help earnings in 2022. But the company will face pressure from pharmaceutical price increases, uncertain revenue from COVID-19 tests and vaccines and moving to a $15 minimum wage across the company, he said.
CVS on Wednesday announced it will raise the minimum wage to $15 an hour from $11 effective July next year.
The wage change, a potential U.S. corporate tax rate rise due to Biden administration policy initiatives and COVID-19 challenges could pose a threat to CVS' 2022 growth target, Morningstar analyst Julie Utterback said.
After beating Wall Street's second-quarter adjusted profit estimates by 36 cents, CVS increased its 2021 adjusted earnings forecast to $7.70 to $7.80 per share, from its prior view of $7.56 to $7.68.
Shares rose 3%, or $2.55, to $81.24.
(Reporting by Amruta Khandekar and Manojna Maddipatla in Bengaluru and Caroline Humer in New York; Editing by Shounak Dasgupta and Bill Berkrot)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chipotle Mexican Grill (CMG) Gets a New Street-High PT of $2,600 at Piper Sandler
- FDA advisers vote to oppose Pfizer/BioNTech COVID-19 vaccine booster
- Oppenheimer Sees Limited Upside for Costco Wholesale (COST) Near Term
Create E-mail Alert Related CategoriesEarnings, General News, Reuters
Related EntitiesMorningstar, Inc., Raising Prices, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!